Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair

Zonneville et al. show that p53 mutant cancers express high levels of the Base Excision Repair (BER) pathway and that deoxyuridine analogues induce DNA damage in p53-mutant TNBC cells. They exploit this genetic liability for therapeutic purposes using a combination of fluorinated deoxyuridine analog...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Justin Zonneville, Moyi Wang, Mohammed M. Alruwaili, Brandon Smith, Megan Melnick, Kevin H. Eng, Thomas Melendy, Ben Ho Park, Renuka Iyer, Christos Fountzilas, Andrei V. Bakin
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/82a83cc457434b04a6a0abf6527d94ee
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!